Jeff Meacham

I want to get some perspectives from you on penetration into primary prevention and where it could go

on Pumitamig, I wanted to check on the cadence of data in, say, the next 6 to 12 months?

just to talk through the Qvantig dynamics versus Opdivo and where you're seeing the biggest demand?

How would you guys characterize the speed of reimbursement and maybe the depth of prescribers in the U.S.

can you give us a sense of your priorities and maybe approach to development for a diversified portfolio like Bristol's

are there any that you would call out or maybe you can still achieve the objective of either line extensions or label expansion

the flexibility of transfer pricing assumptions either maybe from an IP or tax or side of manufacturing

given recent deals, you know, for Chinese assets, but also how low valuations are across US SMID biotech

can you talk about, at a high level, the margins under a wide range of price scenarios for for Lilly

can you talk about how you guys see the competitive setup and related, I know you have prep coming up

Can you guys speak to trends on duration of therapy or maybe real-world safety tolerability

give us a bit more context for not moving to Phase III, maybe what was observed in the data